Dr. Brian Carney, M.D

Hematology & Oncology Boston, MA Male
NPI: 1255779252
Total Payments
$12,156
2024 Payments
$10,519
Companies
7
Transactions
25
Medicare Patients
836
Medicare Billing
$137,063

Payment Breakdown by Category

Consulting$8,979 (73.9%)
Research$1,333 (11.0%)
Travel$1,243 (10.2%)
Food & Beverage$601.90 (5.0%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $8,979 4 73.9%
Unspecified $1,333 12 11.0%
Travel and Lodging $1,243 3 10.2%
Food and Beverage $601.90 6 5.0%

Payments by Type

General
$10,823
13 transactions
Research
$1,333
12 transactions

Top Paying Companies

Company Total Records Latest Year
GENZYME CORPORATION $9,207 8 $0 (2024)
Shire North American Group Inc $1,333 12 $0 (2019)
BeiGene USA, Inc. $675.00 1 $0 (2024)
AstraZeneca Pharmaceuticals LP $525.00 1 $0 (2024)
SOBI, INC $200.00 1 $0 (2024)
Genentech USA, Inc. $109.65 1 $0 (2019)
Mallinckrodt Enterprises LLC $106.48 1 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2024 $10,519 10 GENZYME CORPORATION ($9,119)
2021 $88.39 1 GENZYME CORPORATION ($88.39)
2019 $1,549 14 Shire North American Group Inc ($1,333)

All Payment Transactions

25 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
12/12/2024 AstraZeneca Pharmaceuticals LP Truqap (Drug) Consulting Fee Cash or cash equivalent $525.00 General
Category: Oncology
11/26/2024 BeiGene USA, Inc. BRUKINSA (Drug) Consulting Fee Cash or cash equivalent $675.00 General
Category: Oncology
08/07/2024 SOBI, INC VONJO (Drug) Consulting Fee Cash or cash equivalent $200.00 General
Category: HEMATOLOGY/ONCOLOGY
03/09/2024 GENZYME CORPORATION — Consulting Fee Cash or cash equivalent $7,578.50 General
03/09/2024 GENZYME CORPORATION — Travel and Lodging In-kind items and services $750.38 General
03/09/2024 GENZYME CORPORATION — Travel and Lodging In-kind items and services $265.84 General
03/09/2024 GENZYME CORPORATION — Travel and Lodging In-kind items and services $226.66 General
03/09/2024 GENZYME CORPORATION — Food and Beverage In-kind items and services $200.04 General
03/09/2024 GENZYME CORPORATION — Food and Beverage In-kind items and services $75.07 General
03/09/2024 GENZYME CORPORATION — Food and Beverage In-kind items and services $22.27 General
10/05/2021 GENZYME CORPORATION CABLIVI (Biological) Food and Beverage In-kind items and services $88.39 General
Category: Hematology
10/10/2019 Mallinckrodt Enterprises LLC CELLEX/XTS PHOTOPHERESIS SYSTEM (Device) Food and Beverage In-kind items and services $106.48 General
Category: CRITICAL CARE
05/10/2019 Genentech USA, Inc. HEMLIBRA (Biological) Food and Beverage In-kind items and services $109.65 General
Category: Hematology
03/28/2019 Shire North American Group Inc — — Cash or cash equivalent $206.31 Research
Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT
03/28/2019 Shire North American Group Inc — — Cash or cash equivalent $199.00 Research
Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT
03/28/2019 Shire North American Group Inc — — Cash or cash equivalent $199.00 Research
Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT
03/28/2019 Shire North American Group Inc — — Cash or cash equivalent $60.00 Research
Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT
03/28/2019 Shire North American Group Inc — — Cash or cash equivalent $44.00 Research
Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT
03/28/2019 Shire North American Group Inc — — Cash or cash equivalent $25.00 Research
Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT
03/27/2019 Shire North American Group Inc — — Cash or cash equivalent $60.00 Research
Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT
03/27/2019 Shire North American Group Inc — — Cash or cash equivalent $44.00 Research
Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT
03/27/2019 Shire North American Group Inc — — Cash or cash equivalent $25.00 Research
Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT
03/27/2019 Shire North American Group Inc — — Cash or cash equivalent $25.00 Research
Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT
03/26/2019 Shire North American Group Inc — — Cash or cash equivalent $130.00 Research
Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT
03/20/2019 Shire North American Group Inc — — Cash or cash equivalent $315.60 Research
Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT

Research Studies & Clinical Trials

Study Name Company Amount Records
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT Shire North American Group Inc $1,333 12

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 7 186 265 $100,892 $23,852
2022 9 244 411 $144,516 $36,218
2021 7 202 416 $144,061 $37,923
2020 8 204 442 $153,014 $39,070
Total Patients
836
Total Services
1,534
Medicare Billing
$137,063
Procedure Codes
31

All Medicare Procedures & Services

31 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 54 80 $26,080 $5,962 22.9%
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes Facility 2023 40 40 $26,000 $5,693 21.9%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2023 28 28 $16,968 $4,112 24.2%
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes Facility 2023 14 38 $12,730 $3,383 26.6%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2023 22 38 $8,398 $1,846 22.0%
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes Facility 2023 16 24 $5,592 $1,541 27.6%
99443 Telephone medical discussion with physician, 21-30 minutes Facility 2023 12 17 $5,124 $1,316 25.7%
99233 Follow-up hospital inpatient care per day, typically 35 minutes Facility 2022 25 91 $30,485 $7,966 26.1%
99223 Initial hospital inpatient care per day, typically 70 minutes Facility 2022 42 42 $27,300 $7,039 25.8%
99232 Follow-up hospital inpatient care per day, typically 25 minutes Facility 2022 42 91 $21,203 $5,398 25.5%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 47 71 $23,146 $5,300 22.9%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2022 23 23 $13,938 $3,414 24.5%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2022 27 42 $9,282 $2,281 24.6%
99443 Telephone medical discussion with physician, 21-30 minutes Facility 2022 15 25 $7,096 $1,790 25.2%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 12 15 $7,215 $1,758 24.4%
99222 Initial hospital inpatient care per day, typically 50 minutes Facility 2022 11 11 $4,851 $1,271 26.2%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 43 169 $56,807 $15,305 26.9%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2021 44 105 $24,505 $6,615 27.0%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2021 30 30 $19,500 $5,268 27.0%
99205 New patient outpatient visit, total time 60-74 minutes Facility 2021 31 31 $18,786 $4,809 25.6%
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 27 46 $14,930 $3,475 23.3%
99239 Hospital discharge day management, more than 30 minutes Facility 2021 14 14 $4,892 $1,318 26.9%
99213 Established patient outpatient visit, total time 20-29 minutes Facility 2021 13 21 $4,641 $1,134 24.4%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2020 57 210 $72,030 $19,048 26.4%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2020 39 39 $25,974 $6,894 26.5%
12»

About Dr. Brian Carney, M.D

Dr. Brian Carney, M.D is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2013. The National Provider Identifier (NPI) number assigned to this provider is 1255779252.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Carney, M.D has received a total of $12,156 in payments from pharmaceutical and medical device companies, with $10,519 received in 2024. These payments were reported across 25 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($8,979).

As a Medicare-enrolled provider, Carney has provided services to 836 Medicare beneficiaries, totaling 1,534 services with total Medicare billing of $137,063. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.

Practice Information

  • Specialty Hematology & Oncology
  • Location Boston, MA
  • Active Since 06/12/2013
  • Last Updated 07/01/2019
  • Taxonomy Code 207RH0003X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1255779252

Products in Payments

  • BRUKINSA (Drug) $675.00
  • Truqap (Drug) $525.00
  • VONJO (Drug) $200.00
  • HEMLIBRA (Biological) $109.65
  • CELLEX/XTS PHOTOPHERESIS SYSTEM (Device) $106.48
  • CABLIVI (Biological) $88.39

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Hematology & Oncology Doctors in Boston

Dr. Julio Hajdenberg, Md, MD

Hematology & Oncology — Payments: $1.1M

Hematology & Oncology $1.1M

Dr. Eric Jacobsen, Md, MD

Hematology & Oncology — Payments: $1.1M

Hematology & Oncology $1.1M

Paul Richardson, Md, MD

Hematology & Oncology — Payments: $920,265

Hematology & Oncology $920,265

Matthew Davids, M.d, M.D

Hematology & Oncology — Payments: $808,362

Hematology & Oncology $808,362

David Avigan, M.d, M.D

Hematology & Oncology — Payments: $679,225

Hematology & Oncology $679,225

Anthony Letai, Md, MD

Hematology & Oncology — Payments: $569,795

Hematology & Oncology $569,795